Zydus Lifesciences
-
{
- All
- News
-
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
- Wednesday September 9, 2026
- Author: Nikita Prasad
A majority of companies within Nomura's coverage universe outpaced the broader pharma market in August. Zydus Lifesciences and Glenmark Pharmaceuticals posted the strongest YoY value expansion.
-
www.ndtvprofit.com
-
Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection
- Friday August 21, 2026
- Author: Nikhil Tiwari
Zydus Lifesciences shares rose 1.67% from the day's low to Rs 1,117.80 after the company received final USFDA approval for Ascorbic Acid Injection USP.
-
www.ndtvprofit.com
-
Zydus Life Q1 Result: Net Profit Falls 36% YoY Despite 22% Revenue Growth; Margin Contracts
- Tuesday August 11, 2026
- Author: NDTV Profit Desk
At the operating front, earnings before interest, tax, depreciation and amortisation (EBITDA) declined 7.6% annually to Rs 1,930 crore from Rs 2,089 crore.
-
www.ndtvprofit.com
-
Zydus Lifesciences Approves Buyback Worth Rs 1,100 Crore: Check Record Date
- Tuesday May 19, 2026
- Author: NDTV Profit Desk
Zydus Life Share Buyback: The pharmaceutical major set May 29 as the record date for the payment of the share buyback.
-
www.ndtvprofit.com
-
Zydus Lifesciences To Pay $120 Million To Astellas To Settle Patent Litigation
- Thursday February 12, 2026
- Author: Press Trust of India
Zydus Pharmaceuticals USA, Inc USA, a wholly owned subsidiary of the company, has entered into a settlement agreement with Astellas in relation to its drug Myrbetriq.
-
www.ndtvprofit.com
-
Lupin, Zydus Lifesciences Among DRChoksey’s Top Picks As Pharma Sector Braces For Q3 — Check Full List
- Wednesday January 7, 2026
- Author: Deven Choksey Research
Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.
-
www.ndtvprofit.com
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
- Monday January 5, 2026
- Author: Motilal Oswal Financial Services
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
www.ndtvprofit.com
-
Zydus To Export Medicines To Afghanistan, Establish Local Facility As India-Taliban Ties Improve
- Friday November 28, 2025
- Author: Shubhayan Bhattacharya
Zydus Life signed a memorandum of understanding worth $100 million with Kabul-based Raoufi Group in the UAE on Thursday.
-
www.ndtvprofit.com
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
- Monday November 24, 2025
- Author: Systematix Institutional Equities
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
www.ndtvprofit.com
-
Zydus Lifesciences Q2 Review: ICICI Securities Maintains 'Hold', Sees 4% Downside — Check New Target Price
- Friday November 7, 2025
- Author: ICICI Securities
ICICI Securities raises Zydus Lifesciences FY26/27E earnings by ~2-3% to factor higher sales from recent acqusitions in consumer wellness, medtech divisions.
-
www.ndtvprofit.com
-
LIC, Mankind Pharma, Aurobindo Pharma, Godrej Properties, Birlasoft, Metropolis, Symphony & More Q2 Review
- Friday November 7, 2025
- Author: HDFC Securities Institutional Equities
HDFC Securities recommends 'Add' rating for LIC, Aurobindo Pharma, Star Cement, Metropolis, Godrej Properties 'Buy' Symphony, Astral, 'Reduce' Alkyl Amines, Clean Science - here's why
-
www.ndtvprofit.com
-
Zydus Gets USFDA's Orphan Drug Designation For Beta-Thalassemia Product
- Thursday November 6, 2025
- Author: PTI
Beta thalassaemia patients have low levels of haemoglobin, which results in a lack of oxygen in many parts of the body, leading to weakness, fatigue and more serious complications.
-
www.ndtvprofit.com
-
Dr Reddy's, Zydus Recall Drugs In US Over Manufacturing Issues: USFDA
- Sunday October 12, 2025
- Author: PTI
The USFDA stated that the US-based arm of Zydus Lifesciences is recalling over 1,500 boxes of an antiviral medication used primarily to treat chronic hepatitis B virus.
-
www.ndtvprofit.com
-
Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks
- Thursday October 9, 2025
- Author: ICICI Securities
Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.
-
www.ndtvprofit.com
-
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
- Wednesday September 9, 2026
- Author: Nikita Prasad
A majority of companies within Nomura's coverage universe outpaced the broader pharma market in August. Zydus Lifesciences and Glenmark Pharmaceuticals posted the strongest YoY value expansion.
-
www.ndtvprofit.com
-
Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection
- Friday August 21, 2026
- Author: Nikhil Tiwari
Zydus Lifesciences shares rose 1.67% from the day's low to Rs 1,117.80 after the company received final USFDA approval for Ascorbic Acid Injection USP.
-
www.ndtvprofit.com
-
Zydus Life Q1 Result: Net Profit Falls 36% YoY Despite 22% Revenue Growth; Margin Contracts
- Tuesday August 11, 2026
- Author: NDTV Profit Desk
At the operating front, earnings before interest, tax, depreciation and amortisation (EBITDA) declined 7.6% annually to Rs 1,930 crore from Rs 2,089 crore.
-
www.ndtvprofit.com
-
Zydus Lifesciences Approves Buyback Worth Rs 1,100 Crore: Check Record Date
- Tuesday May 19, 2026
- Author: NDTV Profit Desk
Zydus Life Share Buyback: The pharmaceutical major set May 29 as the record date for the payment of the share buyback.
-
www.ndtvprofit.com
-
Zydus Lifesciences To Pay $120 Million To Astellas To Settle Patent Litigation
- Thursday February 12, 2026
- Author: Press Trust of India
Zydus Pharmaceuticals USA, Inc USA, a wholly owned subsidiary of the company, has entered into a settlement agreement with Astellas in relation to its drug Myrbetriq.
-
www.ndtvprofit.com
-
Lupin, Zydus Lifesciences Among DRChoksey’s Top Picks As Pharma Sector Braces For Q3 — Check Full List
- Wednesday January 7, 2026
- Author: Deven Choksey Research
Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.
-
www.ndtvprofit.com
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
- Monday January 5, 2026
- Author: Motilal Oswal Financial Services
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
www.ndtvprofit.com
-
Zydus To Export Medicines To Afghanistan, Establish Local Facility As India-Taliban Ties Improve
- Friday November 28, 2025
- Author: Shubhayan Bhattacharya
Zydus Life signed a memorandum of understanding worth $100 million with Kabul-based Raoufi Group in the UAE on Thursday.
-
www.ndtvprofit.com
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
- Monday November 24, 2025
- Author: Systematix Institutional Equities
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
www.ndtvprofit.com
-
Zydus Lifesciences Q2 Review: ICICI Securities Maintains 'Hold', Sees 4% Downside — Check New Target Price
- Friday November 7, 2025
- Author: ICICI Securities
ICICI Securities raises Zydus Lifesciences FY26/27E earnings by ~2-3% to factor higher sales from recent acqusitions in consumer wellness, medtech divisions.
-
www.ndtvprofit.com
-
LIC, Mankind Pharma, Aurobindo Pharma, Godrej Properties, Birlasoft, Metropolis, Symphony & More Q2 Review
- Friday November 7, 2025
- Author: HDFC Securities Institutional Equities
HDFC Securities recommends 'Add' rating for LIC, Aurobindo Pharma, Star Cement, Metropolis, Godrej Properties 'Buy' Symphony, Astral, 'Reduce' Alkyl Amines, Clean Science - here's why
-
www.ndtvprofit.com
-
Zydus Gets USFDA's Orphan Drug Designation For Beta-Thalassemia Product
- Thursday November 6, 2025
- Author: PTI
Beta thalassaemia patients have low levels of haemoglobin, which results in a lack of oxygen in many parts of the body, leading to weakness, fatigue and more serious complications.
-
www.ndtvprofit.com
-
Dr Reddy's, Zydus Recall Drugs In US Over Manufacturing Issues: USFDA
- Sunday October 12, 2025
- Author: PTI
The USFDA stated that the US-based arm of Zydus Lifesciences is recalling over 1,500 boxes of an antiviral medication used primarily to treat chronic hepatitis B virus.
-
www.ndtvprofit.com
-
Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks
- Thursday October 9, 2025
- Author: ICICI Securities
Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.
-
www.ndtvprofit.com